NVAX Key Stats
|Revenue (Quarterly YoY Growth)||-16.70%|
|EPS Diluted (TTM)||-0.2954|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-45.96M|
|Gross Profit Margin (Quarterly)||52.60%|
|Profit Margin (Quarterly)||-318.6%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- 5 Stocks Under $10 Set to Soar Nov 21
- Novavax (NVAX) Could Catch a Bid as World Catches a Flu - FBR Capital Street Insider Nov 18
- Pre-Open Stock Movers 11/14: (PLUG) (NVAX) (SCTY) Higher; (CSCO) (KSS) (WMT) Lower (more...) Street Insider Nov 14
- NEJOM Publishes Positive Data on Novavax' Vaccine Against H7N9 Avian Flu Street Insider Nov 13
- Trading Radar for 11/07: Disney (DIS), Tim Hortons (THI), FireEye (FEYE), Groupon (GRPN) Report Street Insider Nov 6
- Two Speculative Biotech Stocks Oct 31
- Novavax to Report Third Quarter 2013 Financial Results on November 7, 2013 noodls Oct 30
- NOVAVAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits Oct 30
- Wednesday's Top Upgrades (and Downgrades) Fool Oct 30
- Buy Novavax On Vaccine Market Growth Oct 30
NVAX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Novavax is up 132.1% over the last year vs S&P 500 Total Return up 30.90%, Anacor Pharmaceuticals up 215.0%, and Omeros up 0.14%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for NVAX
Pro Report PDF for NVAX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download NVAX Pro Report PDF
Pro Strategies Featuring NVAX
Did Novavax make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Novavax, Inc. is a clinical-stage biopharmaceutical company engaged in creating differentiated, value- upon current preventive options for various infectious diseases.